|
|
 |
SphygmoCor® Px Central Blood Pressure Assessment and Management System | | | General Information | |
| Vendor | | AtCor Medical Pty Ltd. | | Item | | SphygmoCor® Px Central Blood Pressure Assessment and Management System | | Features | | The SphygmoCor® Px Central Blood Pressure Assessment and Management System has transformed cardiovascular evaluation, enhancing patient assessment and management by providing the following information:
- Evaluation of systemic arterial stiffness (Aortic Augmentation Index) and its clinical impact on the heart in increasing patient risk of heart failure, stroke and myocardial ischaemia.
- Augmentation pressure, which drives left ventricular load (afterload) - a key parameter affecting risk of LV hypertrophy.
- Central Pulse pressure in the ascending aorta (driving cerebral blood flow) giving the true pressure, and hence the risk of stroke.
- Central systolic pressure, often markedly different from the cuff value.
- Ejection duration – a parameter for distinguishing primarily systolic from primarily diastolic dysfunction, and for managing the efficacy of heart failure therapy.
- Diastolic pressure-time index (DPTI), a key determinant of coronary blood supply.
- Systolic pressure-time index (SPTI), a measure of myocardial oxygen demand.
- Subendocardial Viability Ratio – the relationship of DPTI and SPTI, providing a powerful index for risk stratification for myocardial ischaemia.
| | Approval | | - IEC/EN 60601-1 (amendment 1 & 2) & IEC/EN 60601-1-2 (AS/NZS 3200.1.0 AS/NZS 3200.1.2) Electromedical Safety Certification (this is a mandatory requirement for medical equipment to be used in hospitals in some countries). Rating – "Type CF Class 2”
- Device listing with the Australian Therapeutic Goods Administration (TGA)
- CE Mark (MDD Annex II)
- MLHW registration for Japan
- KFDA Approval for Korea
- Import License for China
| | Product Number | | Inquire | | Applications | | - Evaluation of arterial stiffness and its impact on the heart, giving clinicians an increased ability to assess disease progression and patient risk.
- Hypertension: Improved patient evaluation in hypertension by providing a more comprehensive cardiovascular assessment allowing more effective
- treatment and patient management decisions.
- Diabetes: Improved patient treatment in diabetes through early identification of "at risk" diabetes patients.
- Heart failure: Differentiation between primarily systolic and primarily diastolic heart failure, and management of the progression of diastolic heart failure.
- Titrating Therapy: Monitoring drug interventions by assessing their effects at the heart and titrating therapy accordingly.
- Renal: Measures of arterial stiffness have been shown to be powerful independent predictors of mortality in end-stage renal disease.
| | Pricing |  |  |
| | Related Content | |
| | Product Description | |
| The SphygmoCor® Px Central Blood Pressure Assessment and Management System provides a non-invasive method of obtaining central blood pressure and other key cardiovascular data, and is intended to enhance the treatment and management of patients.
Using a validated generalized transfer function, the system derives the ascending aortic blood pressure waveform from the radial arterial pressure waveform. SphygmoCor then analyzes the central aortic waveform to central pressures and other provide key indices of arterial stiffness and cardiovascular risk. These indices include aortic augmentation pressure, aortic augmentation index, ejection duration, and Buckberg Index (subendocardial viability ratio). Data are reported against age- and gender-specific reference normals.
Read more about the benefits of central blood pressure assessment:
"Central Pressure: Variability and Impact of Cardiovascular Risk Factors. The Anglo-Cardiff Collaborative Trial”
- Over 70% of patients with high normal blood pressure at risk
- Central pressure cannot be reliably inferred from brachial pressure
Read more in the journal Hypertension
"Central Pressure More Strongly Relates to Vascular Disease and Outcome Than Does Brachial Pressure. The Strong Heart Study”
- Noninvasively-determined central pulse pressure is more strongly related to vascular hypertrophy, extent of atherosclerosis, and cardiovascular events than is brachial blood pressure
Read more about the outcomes of the Strong Heart Study in the journal Hypertension.
| | Go to Vendor Product Page | | Go to Vendor Website | |
 |
|
 |
| AtCor Medical Pty Ltd. | | Customer Service: (630) 799-8217 | |
| NOTE: Medcompare disclaims any information on this site. The information found on Medcompare (Drug Guide, Product Listings and otherwise) is intended for use by medical professionals. This information is not intended to replace the information, advice or instructions from a medical doctor. Pricing information is approximate, actual prices may vary. |
|
|
